Articles

Since the start of his second term, President Trump has doubled, tripled, and quadrupled down on his threat to impose tariffs on pharmaceuticals. Is it just bluster?

The deadline for imposing a 100% tariff on branded pharmaceuticals passed, without going into effect, as the Trump administration looks to strike deals to lower drug prices.

The drugmaker secured a three-year reprieve for its products from tariffs under a Section 232 investigation, provided it further invests in U.S. manufacturing.

At the agency’s public meeting on the proposed PreCheck framework, companies said reductions in inspection-related delays could significantly de-risk and reduce timelines.

In the fast-changing pharmaceutical sector, packaging is more critical than ever to patient safety and product provenance.

The Michigan-based pharmaceutical contract manufacturer is investing $2 billion in seven planned plants, with an injectable production facility already completed.

Kenneth Bilenberg, who took the helm mid-September, says the biologics CDMO is preparing for growth in the U.S. biomanufacturing market.

The facility will include labs and simulated cleanrooms, as well as expanded programming, designed to train workers for high-demand technical jobs.

In a post on Truth Social, President Trump warned that companies who are not “building” their pharmaceutical manufacturing plants in the U.S. will be hit with tariffs.

Companies are competing to secure construction workers including electricians in the Tar Heel State, where biotechnology ranks as the fastest growing sector.

The Holly Springs facility represents one of the largest commercial-scale cell culture biomanufacturing sites in North America, according to the company.

The active pharmaceutical ingredient site will focus on domestic production of small molecule synthetic medicines, including Lilly's first oral GLP-1 receptor agonist.

Standing up GMP facilities in the United States takes approximately 32 months given permitting hurdles, say CDMOs who spoke with Leerink Partners analysts.

The agency is reviewing clinical trials that involve sending U.S. patients’ living cells to China and other “hostile countries” for genetic engineering and return infusion.

The Danish drugmaker has been conspicuously absent in 2025 from the flurry of high-profile Big Pharma commitments to invest billions of dollars in the United States.

Collaborative robots are proving their value by boosting efficiency, cutting costs, and scaling access to life-saving medicines.

A $1.2 billion investment covers new AI and digital technology capabilities for its existing five manufacturing sites in Maryland, Montana, North Carolina, and Pennsylvania.

Part of Eli Lilly’s planned $27 billion U.S. investment, the new site will develop active pharmaceutical ingredients for cancer, autoimmune, and other advanced therapies.

The Chinese CRDMOs are not named as biotech companies of concern to U.S. national security in proposed amendment to Fiscal Year 2026 National Defense Authorization Act.

Sun’s factory is under Import Alert until it becomes compliant with FDA and cGMP standards, while Hikal was hit with a warning letter due to repeated metal contamination.

Despite industry setbacks with adeno associated virus-based gene therapy programs, the issue is “largely overblown” for Repligen, contend Leerink Partners analysts.

Software platforms can seamlessly integrate with emerging technologies to unlock efficiencies, strengthen sustainability and enable proactive prevention of disruptions.

William Blair analysts contend the Swiss-headquartered CDMO has a leading position in the attractive, but often underappreciated, small-molecule drug manufacturing space.

The wildly popular drugs, prescribed for weight loss and type 2 diabetes, are putting a strain on the capabilities of contract development and manufacturing organizations.

Large biopharma companies in recent months have pledged billions of dollars in capital expenditures for U.S. manufacturing and R&D facilities. What if it’s not accurate?

The India-based CDMO’s 80,000 square-foot facility in Hopewell, New Jersey includes drug substance manufacturing suites, laboratories, storage, dispensing and warehousing.

The family-owned business is expanding capacity for handling complex injectables, while positioning for growth in drug product development, device assembly and packaging.

Having an effective strategy so products remain free from contaminants is essential to pharmaceutical manufacturing to prevent delays, product recalls, and patient harm.

A second report in as many weeks makes the case that Indian CRDMOs are positioned to take advantage of a global supply chain shakeup and Chinese firms stand to lose.

In a cabinet meeting, President Trump ratcheted up pressure on drugmakers as HHS Secretary Robert F. Kennedy Jr. said his department is “deep” into MFN negotiations.